April 10, 2014

A tumor-suppressing protein acts as a dimmer switch to dial down gene expression. It does this by reading a chemical message attached to another protein that's tightly intertwined with DNA, a team led by scientists at The University of Texas MD Anderson Cancer Center reported at the AACR Annual Meeting 2014.

The findings, also published in the journal Nature on April 10, provide evidence in support of the "histone code" hypothesis. The theory holds that histone proteins, which combine with DNA to form chromosomes, are more intimately involved in gene expression than their general role of facilitating or hindering gene activation suggests.

The researchers found that high expression of the tumor-suppressor ZMYND11 is associated with longer survival for patients with triple-negative breast cancer.

"This study, for the first time, identifies a novel role of a histone variant protein in regulating gene transcription aside from its established roles," said senior author Xiaobing Shi, Ph.D., assistant professor of Biochemistry and Molecular Biology at The University of Texas MD Anderson Cancer Center.

"We also found that this variant, H3.3, is modified by methylation to create a specific epigenetic landscape that is accommodated by the tumor-suppressing protein ZMYND11. The protein in turn blocks gene activation," Shi said. "This is exactly the type of combined effect predicted by the histone code hypothesis."

Methylation, the attachment of a methyl group to a gene or protein, and other types of histone modifications are considered epigenetic factors, which modify a gene's behavior without changing its DNA coding.

Shi and colleagues found that the protein ZMYND11 "reads" the modified histone H3.3 by connecting to it where a tri-methyl chemical group binds to H3.3. From this position, Shi said, ZMYND11 thwarts a step in gene activation called elongation, inhibiting cancer growth.

ZMYND11 expression shrinks tumors in mice

Extensive structural analysis established that the ZMYND11- methylated H3.3 combination hunkers down in the gene's DNA.

"We knew ZMYND11 was a candidate tumor-suppressor because it's down-regulated in a number of human cancers, including breast cancer," Shi said.

Overexpression of ZMYND11 in an osteosarcoma cell line and a triple-negative breast cancer cell line inhibited tumor growth. Versions of ZMYND11 that could not bind to the trimethyl group on H3.3 did not suppress cancer cell growth or survival.

In a mouse model of triple-negative breast cancer, mice injected with cancer cells that over-express ZMYND11 had tumor volumes of less than 50 cubic millimeters while control mice and those injected with cells expressing ZMYND11 deficient for binding to the methyl group had tumor volumes ranging from 150 to 400 cubic millimeters at eight weeks.

When the researchers knocked the ZMYND11 gene down in an osteosarcoma cell line, they found 268 genes had increased expression while 370 genes were down-regulated. Further analysis showed some of the activated genes were enriched in small cell lung cancer and other cancer-promoting pathways.

Gene activation begins when a transcription factor connects with the gene's promoter region. An enzyme called polymerase II then moves along the gene's DNA like a zipper, reading the DNA to produce a strand of RNA, a process called elongation. This ends when the polymerase hits the gene's stop signal.

Since their structural research had shown the ZMYND11/H3.3 combination localized in a gene's DNA rather than its promoter region, the team hypothesized that it fine-tunes gene expression during elongation rather than acting as an on-off switch in the gene's promoter region.

Subsequent experiments showed that the polymerase was more active in the gene body when ZMYND11 was suppressed, particularly on genes that ZMYND11 inhibited.

An analysis of ZMYND11 levels in the tumors of 120 triple-negative breast cancer patients showed that those with high levels of the protein had an 80 percent probability of surviving for 10 years while those with low levels had a 50 percent probability.

The researchers are interested in further elucidating the detailed mechanisms by which ZMYND11 controls transcription elongation.

"Although we know that ZMYND11 controls RNA polymerase II travel ratio in the gene body, we still don't know how this protein, which does not physically interact with polymerase II, actually achieves this regulation," Shi said.

"The next thing to do is to generate a knockout mouse model for further in vivo analysis, as the ultimate goal of our research is to move from bench to bedside, and generating a mouse model is a key step during this long journey," Shi said.

Related Stories

A metabolic protein that nourishes cancer cells also activates tumor-promoting genes by loosening part of the packaging that entwines DNA to make up chromosomes, a team led by scientists at The University of Texas MD Anderson ...

Researchers from Fox Chase Cancer Center have shown that NEDD9, a scaffolding protein responsible for regulating signaling pathways in the cell, promotes the growth and spread of epithelial ovarian cancer.

Yale Cancer Center researchers have identified a regulator of gene expression that is responsible for the progression of breast cancer and its metastasis to the lung. The study appears online in Cell Reports.

Stowers Institute Investigator, Ali Shilatifard, Ph.D., will take center stage at a Meet-the-ExpertSession at the 2014 Annual Meeting of the American Association for Cancer Research (AACR) being held April 5th-9th in San ...

Triple-negative breast cancer (TNBC) is one of the most aggressive forms of the disease and affects almost one in seven of the 1.5 million women diagnosed with breast cancer worldwide each year. TNBC tumors are missing three ...

A breast cancer therapy that blocks estrogen synthesis to activate cancer-killing genes sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's ...

Recommended for you

An international team of researchers involving the University of Adelaide is tackling the controversy over what some scientists consider to be a "harmful" hormone, arguing that it could be a game changer in the fight against ...

Breast cancer cells break away and spread to other parts of the body relatively late on in breast tumour development, an international team of scientists has shown. The research, jointly led by Dr Peter Van Loo at the Francis ...

Discovered in the 1970s, tumor suppressors are among the most important proteins in the body. A master regulator of growth—"the guardian of the genome"—the p53 protein monitors cell growth for errors. We rely on suppressors ...

Starting in 1993 and ending in 2001, ten academic medical centers in the United States screened 76,685 men and 78,216 women for prostate, lung, colorectal and ovarian cancers. The question was whether yearly screening could ...

People with head and neck cancers with evidence of human papillomavirus (HPV) infection generally have a better prognosis than people without evidence of infection. A new study in JAMA Oncology suggests that to produce a ...